本論文分析中西醫合併治療的肺癌病患和純西醫治療的肺癌病患的存活時間是否有顯著差異。研究資料是基於大林慈濟及台北慈濟醫院的癌症登記資料庫及門診資料，總共收錄1871筆肺癌病患資料，其中包含228筆採用中西醫合併治療的資料及1643筆採用純西醫治療的資料。論文首先透過卡方檢定得知許多研究變項分布有顯著差異，因此無法直接運用Kaplan-Meier存活分析。論文接著採用Cox風險迴歸分析，將沒有通過等比例假設檢定的研究變項進行分層，並確定有交互作用的研究變項。分析結果顯示採用純西醫治療比採用中西醫合併治療約增加50%的風險並且達到顯著，而中西醫合併治療的存活時間也明顯優於純西醫治療。而本篇論文也發現了8個單味藥與2個方劑在治療肺癌上有顯著的效果，也找出了7組有效的組合藥，約能降低80~90%的死亡風險。 This thesis analyzes whether there is a significant difference in the survival time between lung cancer patients treated with combining traditional Chinese medicine (TCM) and western medicine and lung cancer patients treated with western medicine. The research data is based on the cancer registration database and patient information of Dalin Tzu Chi and Taipei Tzu Chi Hospital. There are a total of 1871 lung cancer patients in the research data including 228 data using the treatment of combined TCM and western medicine and 1643 data using western medicine. The chi-square test shows that there are significant differences in the distribution of many research variables. Therefore, the Kaplan-Meier survival analysis cannot be directly applied. The Cox risk regression analysis is then applied by stratifying the research variables that do not pass the PH assumption and identifying the research variables with interactions. The results of the analysis show that the risk of using western medicine treatment is about 50% higher than that of using combining TCM and western medicine. The survival time of using western medicine treatment is significantly better than that of using western medicine as well. The results of the analysis also shows that there are 8 herbs, 7 bi-herb combinations, and 2 formulas that have the effects of reducing the risk of death by 80 ~ 90% in the treatment of lung cancer.